middl
east
respiratori
syndrom
coronaviru
merscov
emerg
infecti
diseas
grow
global
import
caus
sever
acut
respiratori
diseas
peopl
result
almost
death
high
case
fatal
rate
grow
geograph
distribut
vagu
defin
epidemiolog
novel
pathogen
creat
urgent
need
effect
public
health
countermeasur
includ
safe
effect
treatment
strategi
despit
rel
number
case
date
research
develop
merscov
therapeut
candid
advanc
quickli
review
survey
landscap
effort
assess
potenti
use
affect
popul
respiratori
tract
infect
lead
caus
mortal
resourcelimit
set
account
million
death
year
global
epidemicand
pandemicpron
respiratori
virus
aetiolog
pathogen
mani
case
caus
sever
promin
infecti
diseas
outbreak
past
two
decad
includ
influenza
sever
acut
respiratori
syndrom
sar
pandem
influenza
recent
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
novel
caus
sever
acut
respiratori
ill
first
identifi
saudi
arabian
patient
although
initi
restrict
arabian
peninsula
emerg
pathogen
respect
infect
kill
peopl
four
contin
across
countri
phylogenet
relat
sarscov
merscov
similar
clinic
present
albeit
higher
case
fatal
rate
versu
dromedari
camel
serv
princip
anim
reservoir
viru
zoonot
spillov
dromedari
human
thu
far
driven
cours
epidem
although
humantohuman
transmiss
document
particularli
context
nosocomi
outbreak
spread
merscov
ineffici
unsustain
reflect
estim
reproduct
rate
higher
merscov
envelop
singlestrand
positivesens
rna
viru
compris
genom
code
four
structur
protein
rna
polymeras
typic
coronavirida
famili
figur
immunogen
protein
viru
surfac
glycoprotein
spike
mediat
viral
attach
fusion
via
host
cognat
receptor
dipeptidyl
peptidas
although
broad
principl
viru
life
cycl
mechan
pathogenesi
begin
understood
knowledg
yet
translat
licens
therapi
vaccin
much
work
develop
safe
effect
merscov
countermeasur
centr
vaccin
rel
low
preval
diseas
sporad
natur
case
cluster
dearth
detail
knowledg
chain
transmiss
highlight
need
greater
invest
discoveri
effect
therapeut
secondari
prophylact
regimen
infect
expos
individu
effort
research
develop
treatment
strategi
merscov
acceler
remain
limit
scope
stage
advanc
novel
compound
studi
specif
merscov
molecular
target
treatment
option
investig
licens
repurpos
use
rna
virus
noninfecti
diseas
current
landscap
merscov
therapi
therefor
domin
armamentarium
reposit
drug
vitro
activ
merscov
replic
also
speckl
agent
direct
toward
deriv
host
immun
current
review
survey
landscap
therapeut
product
categori
assess
potenti
advanc
test
develop
respiratori
circulatori
support
preserv
renal
hepat
neurolog
function
prevent
secondari
infect
beyond
implement
basic
principl
critic
care
medicin
immunebas
therapi
use
commonli
sarscov
pandem
current
merscov
epidem
time
yield
equivoc
result
promis
anim
data
combin
treatment
ribavirin
interferon
ifn
improv
clinic
outcom
merscovinfect
nonhuman
primat
nhp
howev
treatment
initi
soon
viral
challeng
hour
window
unlik
replic
realworld
clinic
set
variou
ifn
regimen
combin
ribavirin
intermitt
administ
sever
ill
patient
although
typic
ad
hoc
manner
absenc
systemat
evalu
individu
case
report
uncontrol
case
seri
limit
determin
whether
intervent
work
safe
well
ribavirin
exampl
potent
nucleosid
analogu
use
vari
measur
success
rang
rna
virus
howev
patient
experi
signific
toxic
given
drug
alon
combin
interferon
includ
limit
haemolyt
anaemia
metabol
abnorm
interferon
also
elicit
system
advers
effect
psychiatr
disturb
neutropenia
thu
without
benefit
randomis
control
trial
data
becom
difficult
assess
whether
treatment
wors
diseas
certain
strategi
howev
shown
worsen
clinic
outcom
set
coronaviru
infect
exampl
studi
sar
pandem
show
corticosteroid
use
earli
sarscov
infect
patient
significantli
increas
viral
load
icu
admiss
mortal
role
interferon
therapi
less
clear
current
merscov
epidem
data
show
posit
impact
proxim
outcom
oxygen
inflamm
effect
signific
outcom
like
hospit
stay
longterm
surviv
rapidli
scale
treatment
base
natur
occur
neutralis
antibodi
convalesc
plasma
hyperimmun
globulin
hand
shown
rel
safe
potenti
effect
reduc
mortal
sever
infect
sarscov
influenza
may
hold
promis
merscov
well
strategi
howev
reli
rapid
identif
case
contact
immedi
deploy
product
maxim
impact
one
studi
found
convalesc
plasma
decreas
mortal
sarscov
patient
administ
within
day
ill
network
use
convalesc
plasma
case
cluster
merscov
current
assembl
test
safeti
efficaci
feasibl
howev
actualis
plan
limit
logist
challeng
local
technic
capac
donor
suppli
unfortun
hostderiv
experiment
intervent
yet
demonstr
appreci
benefit
acut
ill
merscovinfect
patient
consist
control
manner
realiti
although
slow
discoveri
advanc
passiv
prophylact
product
deriv
vaccin
infect
anim
human
despit
intens
effort
develop
merscov
vaccin
preval
transmiss
emerg
pathogen
rel
low
make
difficult
defin
target
popul
vaccin
mab
hand
administ
set
outbreak
without
need
discrimin
might
greatest
risk
infect
use
treat
case
earli
natur
histori
postexposur
prophylaxi
case
contact
mab
also
carri
benefit
higher
potenc
greater
specif
extens
prelicens
evalu
consequ
vet
safeti
profil
addit
mab
help
defin
immunogen
epitop
crystallograph
analysi
therebi
provid
atomiclevel
detail
design
better
immunogen
also
proven
effect
therapi
area
cancer
treatment
autoimmun
diseas
manag
although
one
pathogen
respiratori
syncyti
viru
mab
licens
use
number
infecti
diseas
indicationssuch
ebola
viru
diseas
treatment
human
immunodefici
viru
primari
secondari
preventionfor
mab
test
advanc
phase
clinic
trial
wwwclinicaltrialsgov
despit
advantag
timelin
cost
mab
research
develop
r
respect
longer
higher
polyclon
antibodi
prepar
spite
requir
greater
upfront
invest
rigor
test
approv
process
sever
group
identifi
highli
potent
merscov
mab
advanc
preclin
stage
develop
tabl
isol
immunis
anim
micehumanis
micenhp
other
identifi
either
antibodi
human
phage
librari
memori
b
cell
infect
recov
human
survivor
almost
publish
mab
develop
target
receptorbind
domain
rbd
contain
immunogen
epitop
viru
mani
bind
rbd
express
recombin
surfac
live
viru
picomolar
affin
neutralis
merscov
half
maxim
inhibitori
concentr
ic
less
addit
sever
group
demonstr
new
york
blood
center
imunis
mous
rbd
vitro
nih
nation
cancer
institut
human
antibodi
librari
rbd
vitro
nih
niaid
immunis
mous
rbd
nhp
efficaci
regeneron
humanis
mous
rbd
mousenhp
efficaci
tsinghua
univers
human
antibodi
librari
rbd
vitro
rbd
receptor
bind
domain
spike
glycoprotein
spike
domain
contain
rbd
spike
domain
contain
fusion
machineri
journal
viru
erad
protect
efficaci
preand
postexposur
prophylaxi
anim
model
antibodi
target
rbd
potenti
viral
escap
one
mab
thu
may
need
develop
antibodi
vulner
site
investig
use
combin
mab
overcom
potenti
emerg
therapeut
resist
like
mab
direct
site
glycoprotein
alreadi
recov
potent
neutralis
case
one
report
effici
search
potent
neutralis
antibodi
target
epitop
outsid
rbd
could
facilit
detail
understand
atomiclevel
structur
entir
glycoprotein
alreadi
resolv
rbd
success
thu
far
isol
potent
protect
mab
although
signific
like
temper
challeng
advanc
product
licens
fullscal
product
afford
cost
yet
undefin
popul
rel
short
timefram
thu
mab
advanc
along
develop
pipelin
parallel
program
ration
drug
design
discoveri
although
intens
support
care
still
serv
primari
treatment
option
merscov
mab
focu
advanc
r
effort
antivir
therapi
activ
investig
use
sever
ill
patient
two
main
pathway
drug
discoveri
de
novo
develop
repurpos
licens
medic
new
antivir
merscov
howev
ebola
epidem
unanticip
consequ
facilit
develop
one
particular
develop
gilead
scienc
adenin
analogu
incorpor
viral
rna
disrupt
replic
shown
surviv
benefit
nhp
inocul
ebola
viru
advanc
phase
dose
escal
trial
claim
vitro
activ
merscov
well
public
data
pend
similarli
nucleosid
analogu
develop
biocryst
pharmaceut
potenti
treatment
filovirus
coronavirus
rna
virus
addit
small
interf
rna
molecul
peptid
inhibitor
investig
abil
disrupt
merscov
replic
although
product
still
earli
phase
investig
life
cycl
genet
sequenc
new
coronaviru
becom
better
elucid
ration
design
develop
novel
approv
agent
potent
antivir
activ
becom
possibl
advent
highthroughput
screen
licens
compound
small
molecul
also
allow
research
effici
evalu
larg
librari
drug
vitro
antivir
activ
novel
target
date
sever
dozen
licens
drug
report
inhibit
merscov
replic
use
slightli
differ
screen
technolog
differ
group
converg
common
class
compound
includ
nucleosid
analogu
antibacteri
protein
synthesi
inhibitor
kinas
signal
modifi
antimetabolit
antiprotozo
agent
mycophenol
acid
inhibitor
b
lymphocyt
also
found
strong
activ
merscov
rna
virus
west
nile
hepat
c
dengu
one
drug
show
vitro
activ
merscov
lopinavir
howev
test
anim
model
merscovchalleng
marmoset
treat
proteas
inhibitor
better
clinic
patholog
virolog
radiolog
outcom
control
treat
mycophenol
mofetil
addit
two
peptid
develop
potenti
fusion
inhibitor
act
sixhelix
bundl
core
merscov
protein
prevent
proteinmedi
celltocel
fusion
class
compound
may
hold
potenti
beyond
merscov
toward
longterm
object
pancoronaviru
antivir
given
common
life
cycl
pathway
pathogenesi
rna
virus
homolog
protein
structur
across
differ
coronavirus
may
economi
effort
invest
develop
antivir
activ
one
viru
famili
virus
irrespect
breadth
novel
repurpos
compound
treatment
studi
carri
prospect
accord
protocol
plan
collect
qualiti
control
data
serial
biolog
sampl
assess
viral
evolut
biomark
favour
clinic
outcom
recent
infecti
diseas
outbreak
influenza
pandem
influenza
epidem
china
ebola
crisi
west
africa
merscov
outbreak
highlight
need
better
r
prepared
improv
coordin
clinic
test
face
acceler
number
emerg
reemerg
infecti
diseas
abil
armamentarium
countermeasur
clinic
trial
infrastructur
earli
phase
outbreak
critic
mount
effect
public
health
campaign
exampl
sarscov
pandem
caus
case
sever
acut
respiratori
ill
nearli
death
prospect
control
studi
undertaken
determin
optim
manag
diseas
consequ
treatment
option
sarscov
never
defin
clearli
thu
difficult
adapt
merscov
although
global
coordin
result
advanc
urgent
need
novel
countermeasur
merscov
develop
along
faster
timelin
greater
invest
earlier
preclin
develop
pipelin
gener
product
time
efficaci
test
affect
popul
global
commun
take
lesson
recent
outbreak
prepar
potenti
anoth
region
epidem
broader
pandem
stakehold
merscov
r
must
set
sound
strategi
best
target
invest
anticip
chang
dynam
current
futur
outbreak
